Targeting DNA damage response pathways for the treatment of advanced lung cancer
Ended Project Grant Awarded Last action
- Award ID
- R44CA228756
- Recipient
-
Cumberland Pharmaceuticals, Inc. UEI M2ZXA6LYJ3S5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,947,753
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Tennessee, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$15,355 | |
| Amendment | -$15,355 | |
| Amendment | -$5,247 | |
| Amendment | -$5,247 | |
| Amendment | -$5,247 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,070,134 | |
| Amendment | $0 | |
| Original award | $924,071 |
Quick answers
Who received award R44CA228756?
R44CA228756 was awarded to Cumberland Pharmaceuticals, Inc. by National Cancer Institute (National Institutes of Health) on September 11, 2018.
How much is award R44CA228756 worth?
$1,947,753 has been obligated on R44CA228756.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award